Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis.

An Bras Dermatol · 2026 · PMC12813531 · PMID 41512530

Europe PMC DOI

hedged sentence

0.4430

closest p · 8.9× alpha

0.4430

boldest claim

The sentences

did not reach statistical significancep = 0.443not close (p > 0.1)

By 3-months, miltefosine continued to show a numerical advantage, although the difference did not reach statistical significance (RR = 0.89; 95% CI: 0.67, 1.19; p = 0.443; I 2 = 79.9%; Fig. 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.